Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate,vilanterol, Asthma, Date of authorisation: 02/05/2014, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate,vilanterol, Asthma, Date of authorisation: 02/05/2014, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Multiple Sclerosis, Relapsing-Remitting, Date of authorisation: 15/11/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Multiple Sclerosis, Relapsing-Remitting, Date of authorisation: 15/11/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), COVID-19 virus infection, Date of authorisation: 30/03/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), COVID-19 virus infection, Date of authorisation: 30/03/2023, Revision: 2, Status: Authorised

LinkedIn Live interview with Ivo Claassen: Tomorrow's veterinary medicines for healthy animals and humans, Online, 13:15-13:45 Amsterdam time (CEST), from 07/09/2023 to 07/09/2023

LinkedIn Live interview with Ivo Claassen: Tomorrow's veterinary medicines for healthy animals and humans, Online, 13:15-13:45 Amsterdam time (CEST), from 07/09/2023 to 07/09/2023

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.